Focus: Relmada is a public biotech focused on small molecules for pain, neurology, and oncology with a lean 5,000+ employee base headquartered in Florida. The company operates as a clinical-stage player with no approved products generating revenue.
Profile data last refreshed 2h ago · AI intelligence enriched 2mo ago
No open roles listed right now. Follow Relmada Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Relmada Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Relmada Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Biotech Relmada CEO, CFO in Jefferies fireside chat June 4 - Stock Titan
Biotech Relmada CEO, CFO in Jefferies fireside chat June 4 Stock Titan
Relmada Therapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
Relmada Therapeutics Inc Annual Shareholders Meeting Transcript GuruFocus
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2026 Earnings Call Transcript - Insider Monkey
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q1 2026 Earnings Call Transcript Insider Monkey
Relmada Therapeutics Inc files for mixed shelf offering, size not disclosed - SEC filing - marketscreener.com
Relmada Therapeutics Inc files for mixed shelf offering, size not disclosed - SEC filing marketscreener.com
Relmada Therapeutics (NASDAQ: RLMD) registers 29.5M shares tied to $160M deal - Stock Titan
Relmada Therapeutics (NASDAQ: RLMD) registers 29.5M shares tied to $160M deal Stock Titan
Adage Capital reports 4.54% stake in Relmada Therapeutics (NASDAQ: RLMD) - Stock Titan
Adage Capital reports 4.54% stake in Relmada Therapeutics (NASDAQ: RLMD) Stock Titan
Showing 6 of 10 news items
No open positions listed yet. Check their careers page directly.
Recent peer-reviewed publications with author affiliations at this company
New Synthesis and Pharmacological Evaluation of Enantiomerically Pure (R)- and (S)-Methadone Metabolites as N-Methyl-d-aspartate Receptor Antagonists.
Long-Term Safety and Efficacy of Esmethadone in Patients With Major Depressive Disorder: Findings From a 12-Month Open-Label Study.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo